BNC Korea Co., Ltd completed the acquisition of NH Special Purpose Acquisition 11 Co., Ltd. in a reverse merger transaction.
November 14, 2019
Share
BNC Korea Co., Ltd. (XKON:A226610) entered into an agreement to acquire NH Special Purpose Acquisition 11 Co., Ltd. (KOSDAQ:A256840) in a reverse merger transaction on June 3, 2019. The shares will be exchanged at a ratio of 1:6.0084158. NH Special Purpose Acquisition 11 Co., Ltd. will issue 36.2 million new shares to BNC Korea as part of the deal. As per the update on September 2, 2019, the exchange ratio is changed to 1:6.0305419. NH Special Purpose Acquisition 11 Co., Ltd. will issue 36.35 million new shares to BNC Korea as part of the deal. The transaction is subject to approval from the shareholders of NH Special Purpose Acquisition 11 Co., Ltd and BNC Korea. On October 11, 2019, shareholders of BNC Korea Co., Ltd. approved the transaction. The transaction is expected to be completed on November 8, 2019. As of August 22, 2019, completion is scheduled to take place on November 15, 2019. Nexia Samduk acted as external rating institution.
BNC Korea Co., Ltd. completed the acquisition of NH Special Purpose Acquisition 11 Co., Ltd. (KOSDAQ:A256840) in a reverse merger transaction on November 15, 2019.
BNC Korea Co. Ltd, formerly NH Special Purpose Acquisition 11 Co., Ltd., is a Korea-based company principally engaged in the manufacture and sale of biopharmaceuticals. The Company's main products include hyaluronic acid (HA) fillers, collagen wound dressings, antiadhesion materials and collagen tissue supplements, and others. In addition, the Company produces and sells cosmetics, medicines and medical devices, among others.
BNC KOREA CO., LTD. 
